Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study.

Lyritis GP, Ioannidis GV, Karachalios T, Roidis N, Kataxaki E, Papaioannou N, Kaloudis J, Galanos A

The Clinical journal of pain1 Dec 1999Cited by 51 (Europe PMC)

PMID10617256DOI10.1097/00002508-199912000-00004PepBankPUB-10617256

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with recent osteoporotic vertebral fractures, fasting osteocalcin was significantly lower with salmon calcitonin than placebo at day 28.
In plain wordsAt day 28, fasting osteocalcin was significantly lower with salmon calcitonin than placebo in patients with recent osteoporosis-related spine fractures.
Peptide
Calcitonin-salmon
Outcome
DecreaseFasting osteocalcin at day 28
Study
n = 40
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · rectal suppository · 28 daysAs given in this study (human).
Measurements
P
< 0.001
biochemical comparisons
Source sentences
Summary
At the end of the study (28th day), fasting osteocalcin, hydroxyproline/creatinine, and calcium/creatinine ratio values were statistically significantly (all p values < 0.001), lower in the calcitonin-treated than in the placebo-treated patients.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, double-blind, randomized, placebo-controlled, clinical trial.
Summary · context
Forty patients (8 men and 32 postmenopausal women), who had recently (within the last 5 days) suffered a nontraumatic osteoporotic vertebral fracture.
Summary · context
All patients were admitted to the hospital, divided randomly into two groups and received either one calcitonin or placebo suppository once a day, respectively, for 28 days.
Summary · context
All patients were allowed to take paracetamol tablets (500 mg), with a maximum dose of six tablets daily.
Report a problemFND-1061725605
02HumanRandomized controlled trialEfficacy outcome
In patients with recent osteoporotic vertebral fractures, hydroxyproline/creatinine was significantly lower with salmon calcitonin than placebo at day 28.
In plain wordsAt day 28, hydroxyproline/creatinine was significantly lower with salmon calcitonin than placebo in patients with recent osteoporosis-related spine fractures.
Peptide
Calcitonin-salmon
Outcome
DecreaseHydroxyproline/creatinine at day 28
Study
n = 40
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · rectal suppository · 28 daysAs given in this study (human).
Measurements
P
< 0.001
biochemical comparisons
Source sentences
Summary
At the end of the study (28th day), fasting osteocalcin, hydroxyproline/creatinine, and calcium/creatinine ratio values were statistically significantly (all p values < 0.001), lower in the calcitonin-treated than in the placebo-treated patients.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, double-blind, randomized, placebo-controlled, clinical trial.
Summary · context
Forty patients (8 men and 32 postmenopausal women), who had recently (within the last 5 days) suffered a nontraumatic osteoporotic vertebral fracture.
Summary · context
All patients were admitted to the hospital, divided randomly into two groups and received either one calcitonin or placebo suppository once a day, respectively, for 28 days.
Summary · context
All patients were allowed to take paracetamol tablets (500 mg), with a maximum dose of six tablets daily.
Report a problemFND-1061725606
03HumanRandomized controlled trialEfficacy outcome
In patients with recent osteoporotic vertebral fractures, calcium/creatinine was significantly lower with salmon calcitonin than placebo at day 28.
In plain wordsAt day 28, calcium/creatinine was significantly lower with salmon calcitonin than placebo in patients with recent osteoporosis-related spine fractures.
Peptide
Calcitonin-salmon
Outcome
DecreaseCalcium/creatinine at day 28
Study
n = 40
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · rectal suppository · 28 daysAs given in this study (human).
Measurements
P
< 0.001
biochemical comparisons
Source sentences
Summary
At the end of the study (28th day), fasting osteocalcin, hydroxyproline/creatinine, and calcium/creatinine ratio values were statistically significantly (all p values < 0.001), lower in the calcitonin-treated than in the placebo-treated patients.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, double-blind, randomized, placebo-controlled, clinical trial.
Summary · context
Forty patients (8 men and 32 postmenopausal women), who had recently (within the last 5 days) suffered a nontraumatic osteoporotic vertebral fracture.
Summary · context
All patients were admitted to the hospital, divided randomly into two groups and received either one calcitonin or placebo suppository once a day, respectively, for 28 days.
Summary · context
All patients were allowed to take paracetamol tablets (500 mg), with a maximum dose of six tablets daily.
Report a problemFND-1061725607
04HumanNon-randomized trialEfficacy outcome
In patients with recent osteoporotic vertebral fractures, salmon calcitonin significantly reduced spinal pain measured by VAS.
In plain wordsIn patients with recent osteoporosis-related spine fractures, salmon calcitonin significantly reduced pain measured by a visual scale.
Peptide
Calcitonin-salmon
Outcome
DecreaseSpinal pain by VAS
Study
n: not reported in source
Outcome group
Pain · Musculoskeletal
Studied dose
200 IU daily · rectal suppository · 28 daysAs given in this study (human).
Measurements
P
< 0.001
all pain comparisons
Source sentences
Summary
All calcitonin-treated patients experienced an overall statistically significant (all p values < 0.001) decrease of spinal pain as assessed by the VAS and the painmeter device.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, double-blind, randomized, placebo-controlled, clinical trial.
Summary · context
Forty patients (8 men and 32 postmenopausal women), who had recently (within the last 5 days) suffered a nontraumatic osteoporotic vertebral fracture.
Summary · context
All patients were admitted to the hospital, divided randomly into two groups and received either one calcitonin or placebo suppository once a day, respectively, for 28 days.
Summary · context
All patients were allowed to take paracetamol tablets (500 mg), with a maximum dose of six tablets daily.
Report a problemFND-1061725601
05HumanNon-randomized trialEfficacy outcome
In patients with recent osteoporotic vertebral fractures, salmon calcitonin significantly reduced spinal pain measured by a painmeter.
In plain wordsIn patients with recent osteoporosis-related spine fractures, salmon calcitonin significantly reduced pain measured by a pressure device.
Peptide
Calcitonin-salmon
Outcome
DecreaseSpinal pain by painmeter
Study
n: not reported in source
Outcome group
Pain · Musculoskeletal
Studied dose
200 IU daily · rectal suppository · 28 daysAs given in this study (human).
Measurements
P
< 0.001
all pain comparisons
Source sentences
Summary
All calcitonin-treated patients experienced an overall statistically significant (all p values < 0.001) decrease of spinal pain as assessed by the VAS and the painmeter device.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, double-blind, randomized, placebo-controlled, clinical trial.
Summary · context
Forty patients (8 men and 32 postmenopausal women), who had recently (within the last 5 days) suffered a nontraumatic osteoporotic vertebral fracture.
Summary · context
All patients were admitted to the hospital, divided randomly into two groups and received either one calcitonin or placebo suppository once a day, respectively, for 28 days.
Summary · context
All patients were allowed to take paracetamol tablets (500 mg), with a maximum dose of six tablets daily.
Report a problemFND-1061725602
06HumanNon-randomized trialEfficacy outcome
In patients with recent osteoporotic vertebral fractures, pain relief during salmon calcitonin treatment allowed early mobilization.
In plain wordsIn patients with recent osteoporosis-related spine fractures, pain relief during salmon calcitonin treatment allowed early movement.
Peptide
Calcitonin-salmon
Outcome
IncreaseEarly mobilization
Study
n: not reported in source
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
200 IU daily · rectal suppository · 28 daysAs given in this study (human).
Source sentences
Summary
Pain relief allowed for early mobilization and the gradual restoration of the locomotive functions in the calcitonin-treated group.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, double-blind, randomized, placebo-controlled, clinical trial.
Summary · context
Forty patients (8 men and 32 postmenopausal women), who had recently (within the last 5 days) suffered a nontraumatic osteoporotic vertebral fracture.
Summary · context
All patients were admitted to the hospital, divided randomly into two groups and received either one calcitonin or placebo suppository once a day, respectively, for 28 days.
Summary · context
All patients were allowed to take paracetamol tablets (500 mg), with a maximum dose of six tablets daily.
Report a problemFND-1061725603
07HumanNon-randomized trialEfficacy outcome
In patients with recent osteoporotic vertebral fractures, pain relief during salmon calcitonin treatment allowed gradual restoration of locomotive functions.
In plain wordsIn patients with recent osteoporosis-related spine fractures, pain relief during salmon calcitonin treatment allowed gradual recovery of movement functions.
Peptide
Calcitonin-salmon
Outcome
IncreaseLocomotive function restoration
Study
n: not reported in source
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
200 IU daily · rectal suppository · 28 daysAs given in this study (human).
Source sentences
Summary
Pain relief allowed for early mobilization and the gradual restoration of the locomotive functions in the calcitonin-treated group.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, double-blind, randomized, placebo-controlled, clinical trial.
Summary · context
Forty patients (8 men and 32 postmenopausal women), who had recently (within the last 5 days) suffered a nontraumatic osteoporotic vertebral fracture.
Summary · context
All patients were admitted to the hospital, divided randomly into two groups and received either one calcitonin or placebo suppository once a day, respectively, for 28 days.
Summary · context
All patients were allowed to take paracetamol tablets (500 mg), with a maximum dose of six tablets daily.
Report a problemFND-1061725604
08HumanNon-randomized trialSafety outcome
Patients with recent osteoporotic vertebral fractures experienced dizziness during salmon calcitonin suppository treatment.
In plain wordsPatients with recent osteoporosis-related spine fractures had dizziness during salmon calcitonin suppository treatment.
Peptide
Calcitonin-salmon
Outcome
Not applicableDizziness
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
200 IU daily · rectal suppository · 28 daysAs given in this study (human).
Source sentences
Summary
In the calcitonin-treated group side effects mainly included dizziness and enteric irritation caused by the suppositories.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, double-blind, randomized, placebo-controlled, clinical trial.
Summary · context
Forty patients (8 men and 32 postmenopausal women), who had recently (within the last 5 days) suffered a nontraumatic osteoporotic vertebral fracture.
Summary · context
All patients were admitted to the hospital, divided randomly into two groups and received either one calcitonin or placebo suppository once a day, respectively, for 28 days.
Summary · context
All patients were allowed to take paracetamol tablets (500 mg), with a maximum dose of six tablets daily.
Report a problemFND-1061725608
09HumanNon-randomized trialSafety outcome
In patients with recent osteoporotic vertebral fractures, enteric irritation occurred with salmon calcitonin suppositories and also with placebo.
In plain wordsIn patients with recent osteoporosis-related spine fractures, bowel irritation occurred with salmon calcitonin suppositories and also with placebo.
Peptide
Calcitonin-salmon
Outcome
Not applicableEnteric irritation
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
200 IU daily · rectal suppository · 28 daysAs given in this study (human).
Source sentences
Summary
In the calcitonin-treated group side effects mainly included dizziness and enteric irritation caused by the suppositories.
5 context sentences(design, population, supporting numbers)
Summary · context
Enteric irritation was also present in the placebo-treated group.
Summary · context
A prospective, double-blind, randomized, placebo-controlled, clinical trial.
Summary · context
Forty patients (8 men and 32 postmenopausal women), who had recently (within the last 5 days) suffered a nontraumatic osteoporotic vertebral fracture.
Summary · context
All patients were admitted to the hospital, divided randomly into two groups and received either one calcitonin or placebo suppository once a day, respectively, for 28 days.
Summary · context
All patients were allowed to take paracetamol tablets (500 mg), with a maximum dose of six tablets daily.
Report a problemFND-1061725609

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.